Hydroxyurea Dosing Recommendations
Sickle Cell Disease
For children with sickle cell anemia (SCA), initiate hydroxyurea at 9 months of age at 20 mg/kg/day, with consideration for starting as early as 6 months if severe hemolytic anemia or organ damage is present 1. This represents the most current standard of care based on 2025 NASCC guidelines.
Dosing Algorithm for SCA:
Standard starting dose: 20 mg/kg/day orally once daily
Earlier initiation (6 months): Consider if:
- Severe hemolytic anemia present
- Chronic organ damage documented
- Clinical complications occurring
- Parental preference after informed discussion 1
Modified starting dose for non-SCA genotypes: 15 mg/kg/day for hemoglobin SC or Sβ⁺ thalassemia patients with severe disease (≥3 pain admissions per 2 years, acute chest syndrome, or avascular necrosis) due to increased cytopenia risk 1
Dose Escalation Strategy:
The goal is achieving modest, safe myelosuppression through stepwise dose escalation with periodic weight-based adjustments 2. Maximum tolerated dose (MTD) approach is recommended for optimal HbF induction and clinical benefit, though fixed low-dose regimens (~10 mg/kg/day) show comparable vaso-occlusive crisis reduction in some adult studies 3.
Monitoring Requirements:
- Pre-treatment labs: CBC with differential, absolute reticulocyte count, comprehensive metabolic panel with LDH, and HbF percentage 1
- During treatment: CBC at least weekly initially, then adjust frequency based on stability 4
- Annual monitoring: HbF percentage at minimum, more frequently per clinician preference to assess adherence and medication effect 1
Critical Caveat:
Prophylactic folic acid supplementation is recommended 4. The FDA label emphasizes swallowing capsules whole—never open, break, or chew due to cytotoxic nature 4.
Polycythemia Vera (PV)
For high-risk PV requiring cytoreduction, hydroxyurea should be dosed at 15-20 mg/kg/day initially, with target maintenance around 1 gram daily (approximately 15 mg/kg/day) to achieve hematocrit <45% without phlebotomy 5, 6.
Dosing Strategy:
- Loading approach (historical): 30 mg/kg/day for 1 week, then reduce to 15 mg/kg/day 5
- Contemporary approach: Start at 15-20 mg/kg/day to minimize early cytopenia risk 5
- Typical maintenance: ~1 gram/day (range 0.5-2 g/day) 6
Treatment Goals:
- Hematocrit <45% without phlebotomy
- Platelet count ≤400 × 10⁹/L
- WBC count ≤10 × 10⁹/L
- Resolution of disease-related symptoms 7
Hydroxyurea Resistance/Intolerance Criteria (consider switching to ruxolitinib):
The NCCN defines resistance as requiring phlebotomy after 3 months of ≥2 g/day hydroxyurea, or uncontrolled myeloproliferation (platelets >400 × 10⁹/L AND WBC >10 × 10⁹/L) despite ≥2 g/day for 3 months 7. Intolerance includes ANC <1.0 × 10⁹/L, platelets <100 × 10⁹/L, or hemoglobin <10 g/dL at the lowest effective dose, or development of leg ulcers/unacceptable toxicities 7.
Essential Thrombocythemia (ET)
For high-risk ET, initiate hydroxyurea at 15-20 mg/kg/day with dose titration to achieve platelet count <400 × 10⁹/L while avoiding cytopenia 8, 9.
Risk Stratification Determines Treatment:
- Very low/low risk: Aspirin alone (once or twice daily)
- Intermediate risk: Cytoreduction optional
- High risk: Cytoreduction mandatory (age >60 years with JAK2 mutation OR any thrombosis history) 9
Hydroxyurea Resistance/Intolerance Criteria:
- Platelet count >600 × 10⁹/L with WBC <2.5 × 10⁹/L at any dose
- Platelet count >400 × 10⁹/L with hemoglobin <10 g/dL at any dose
- Development of leg ulcers or mucocutaneous manifestations
- Hydroxyurea-related fever 7
Chronic Myeloid Leukemia (CML)
Hydroxyurea is indicated only for resistant CML at individualized doses based on tumor burden and response 4. The FDA label provides no specific dosing algorithm, as tyrosine kinase inhibitors have replaced hydroxyurea as standard therapy. When used historically, doses ranged widely based on WBC count and clinical response.
Universal Dose Modifications
Renal Impairment:
Reduce dose by 50% for creatinine clearance <60 mL/min or ESRD 4:
- CrCl ≥60 mL/min: 15 mg/kg once daily
- CrCl <60 mL/min or ESRD: 7.5 mg/kg once daily
- On dialysis days: Administer after hemodialysis 4
Myelosuppression Management:
Dose reduction or temporary discontinuation required for severe cytopenia. Recovery is typically rapid upon interruption 4. The key principle: modest cytopenia is expected and therapeutic in SCD, but severe suppression requires intervention 2.
Important Safety Considerations:
- Pregnancy Category D: Teratogenic at 0.3-0.8 times human doses in animals. Females require contraception during and 6 months after therapy; males for 1 year after 4
- Carcinogenicity: Secondary leukemia and skin cancers reported with long-term use in myeloproliferative disorders 4
- Hemolytic anemia: Discontinue if confirmed hemolysis occurs in myeloproliferative disease patients 4